Menu
1 min read · estimated
APPROVED USE
What FDA approved
Alternative 500 mg/m² intravenous cetuximab dosing every two weeks for labeled KRAS wild-type, EGFR-expressing metastatic colorectal cancer and squamous cell carcinoma of the head and neck.
LAMPGEN ANALYSIS
Why it matters
The decision adds a biweekly administration option for these existing uses.
What research teams should watch
Update infusion templates and align visit frequency with the combination regimen and specimen collection.
PRIMARY RECORDS